Myriad Genetics to Present PROLARIS® Data at ASCO 2013, Continuing Its Commitment to Cancer Research
"Myriad is a pioneer and global-leader in molecular diagnostic testing for cancer," said
PROLARIS Is the Dominant Predictor of Prostate Cancer Outcomes
Professor Cuzick will present data from an analysis of five clinical studies of PROLARIS on
"Clinical data show that PROLARIS predicts prostate cancer outcome in multiple patient cohorts and in diverse clinical settings," said Professor Cuzick. "PROLARIS provides independent information beyond clinicopathologic variables and accurately differentiates aggressive prostate cancer from indolent cancer based on real oncologic outcomes."
PROLARIS is the molecular prognostic test for both newly diagnosed and post-prostatectomy prostate cancer patients. PROLARIS is being integrated into clinical practice by hundreds of urologists in
Key clinical characteristics of PROLARIS include:
- The PROLARIS Score® is the dominant variable at diagnosis in predicting risk of prostate cancer progression, as determined by the gold standard oncologic endpoints such as biochemical recurrence, metastasis and prostate cancer specific mortality;
- The PROLARIS Score provides personalized risk of cancer progression above that afforded by the Gleason score, clinical stage and PSA level; and
- PROLARIS helps clinicians identify patients who are good candidates for conservative management and patients for whom monotherapy with surgery or radiation therapy may be inadequate.
Myriad Is Trailblazing the Next Generation of
myRisk Hereditary Cancer™
Myriad recently announced its next-generation test for hereditary cancers called myRisk™ Hereditary Cancer. Myriad's myRisk represents a scientific advancement that will revolutionize hereditary cancer testing for appropriate patients. Initially, myRisk will include a 25-gene panel that is focused on clinically-actionable cancers including: breast, colon, ovarian, endometrial, pancreatic, prostate and melanoma. myRisk also will provide healthcare professionals and patients with an easy-to-understand, clinically-actionable report to help guide healthcare decisions and treatments. The company is collaborating with the medical and scientific communities and an early access launch is planned fall 2013.
myPath Melanoma is a molecular diagnostic test that evaluates gene expression targets to help dermatopathologists correctly assess difficult-to-diagnose skin biopsy samples. In
Homologous Repair Deficiency
Homologous Repair Deficiency (HRD) is the most accurate and comprehensive measure of deficiency in DNA repair processes. HRD has been extensively validated in triple negative breast cancer and ovarian cancer and is highly prevalent in other major cancers. Myriad is developing a diagnostic test based on HRD from a tumor sample that will enable healthcare providers to identify and treat patients based on their HRD status and use specific drugs targeted to the DNA repair pathways. The HRD test will be used as a companion diagnostic test along with therapeutics agents, and the company is on track to launch an HRD test for platinum-based therapies in 2015 and ADP ribose polymerase (PARP) inhibitors in 2017.
Myriad Collaborates Externally to Create Opportunities
In addition to the work in its own labs, Myriad is seeking out the best science through external collaborations and partnerships. Myriad recently announced a commercial partnership with its new homologous recombination deficiency test in patients being treated with Pharma Mar's PM1183 drug candidate and has an ongoing collaboration with AstraZeneca to develop a companion diagnostic for ovarian cancer.
Myriad also has research partnerships with numerous academic institutions and research centers including
"Collaborations are vital to our research and development strategy," said Meldrum. "Our track record and commitment to scientific integrity and quality sets us apart from other diagnostic companies and has established Myriad as a preferred partner in molecular diagnostics."
Myriad Supports Education for Genetic Testing
Myriad invests millions of dollars annually to educate the public about cancer and diagnostic testing and to raise awareness of benefits of genetic testing. Examples of our educational programs include:
- Hereditary Cancer Quiz: www.myriad.com/patients/heredtiary-cancer-quiz/
- MySupport360: www.mysupport360.com/
- JustAsk! About HBOC: http://www.youtube.com/user/justaskhboc
- JustAsk! About Lynch: http://www.youtube.com/user/justasklynch
Myriad also supports education and advocacy through several national and local organizations such as Bright Pink, Cancer Wellness House,
"We support increasing education and awareness about cancer and the benefits of molecular diagnostic testing," said Meldrum. "Our educational efforts are focused on helping patients better understand their risks and empowering them take control of their healthcare decisions."
Myriad Is Helping to Increase Patient Access
Myriad has helped thousands of patients gain access to molecular diagnostic testing through its
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of data from five PROLARIS clinical studies in patients with prostate cancer at the
CONTACT: Media Contact:Source:
Ron Rogers(801) 584-3065 firstname.lastname@example.org Investor Contact: Scott Gleason(801) 584-1143 email@example.com
News Provided by Acquire Media